JAK Inhibitors: Mechanism, Uses & Side Effects
JAK inhibitors are prescription medications that selectively block Janus kinases, reducing inflammation in conditions such as rheumatoid arthritis and atopic dermatitis.
Things worth knowing about "JAK inhibitors"
JAK inhibitors are prescription medications that selectively block Janus kinases, reducing inflammation in conditions such as rheumatoid arthritis and atopic dermatitis.
What Are JAK Inhibitors?
JAK inhibitors (Janus kinase inhibitors) are a class of medications that selectively block enzymes known as Janus kinases (JAK). These enzymes play a key role in transmitting inflammatory signals within the body. By inhibiting them, JAK inhibitors can reduce the overactive immune response seen in many chronic inflammatory and autoimmune diseases. They belong to a group called targeted synthetic DMARDs (disease-modifying antirheumatic drugs).
Mechanism of Action
The human body contains four Janus kinases: JAK1, JAK2, JAK3, and TYK2. These enzymes are part of the JAK-STAT signaling pathway, through which many cytokines (immune messenger molecules) exert their effects. When cytokines bind to cell surface receptors, they activate JAK enzymes, which in turn phosphorylate STAT proteins. These then migrate to the cell nucleus and regulate gene expression, including the production of further inflammatory mediators.
JAK inhibitors bind to the active sites of these enzymes, blocking their activity. Different drugs target different JAK subtypes, which explains the varying indications and side effect profiles across the drug class.
Approved Substances and Indications
Several JAK inhibitors are currently approved in the EU and internationally. The most important include:
- Tofacitinib: Approved for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and juvenile idiopathic arthritis (inhibits JAK1 and JAK3).
- Baricitinib: Approved for rheumatoid arthritis, atopic dermatitis, and alopecia areata (inhibits JAK1 and JAK2).
- Upadacitinib: Approved for rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ankylosing spondylitis, and Crohn's disease (selective JAK1 inhibitor).
- Filgotinib: Approved for rheumatoid arthritis (selective JAK1 inhibitor).
- Ruxolitinib: Approved for myelofibrosis, polycythemia vera, and atopic dermatitis (topical formulation) (inhibits JAK1 and JAK2).
- Deucravacitinib: Selective TYK2 inhibitor approved for moderate to severe plaque psoriasis.
Areas of Use
JAK inhibitors are used in a wide range of chronic inflammatory and autoimmune conditions, including:
- Rheumatoid arthritis (RA)
- Psoriatic arthritis
- Atopic dermatitis (eczema)
- Ulcerative colitis and Crohn's disease
- Alopecia areata
- Ankylosing spondylitis
- Myelofibrosis and polycythemia vera (hematological conditions)
Dosage and Administration
Most oral JAK inhibitors are taken as tablets, typically once or twice daily. The exact dosage depends on the specific drug, the indication, and individual patient factors such as kidney function. Some JAK inhibitors are also available as topical formulations (e.g., cream or ointment) for skin conditions. Treatment should always be supervised by a qualified healthcare professional.
Side Effects
JAK inhibitors can cause a range of side effects. Commonly reported adverse effects include:
- Infections: Increased risk of bacterial, viral (including herpes zoster), and opportunistic infections
- Blood count changes: e.g., anemia, neutropenia, thrombocytopenia
- Elevated liver enzymes (transaminase increase)
- Lipid changes: Increases in LDL and HDL cholesterol
- Gastrointestinal complaints: Nausea, diarrhea
- Increased risk of major adverse cardiovascular events (MACE) in certain risk groups
- Increased malignancy risk: Particularly in older patients and smokers
- Thromboembolic events: Deep vein thrombosis, pulmonary embolism (especially at higher doses)
Due to these safety signals, the European Medicines Agency (EMA) has restricted the use of JAK inhibitors in certain high-risk patient groups and issued additional warnings.
Contraindications and Precautions
JAK inhibitors are not suitable for all patients. Special caution is warranted in:
- Active or chronic infections (e.g., tuberculosis, hepatitis)
- Severe renal or hepatic impairment
- Pregnancy and breastfeeding (contraindicated)
- Patients over 65 years of age with additional risk factors (cardiovascular, malignancy, smoking)
- Existing or prior malignancies
JAK Inhibitors Compared to Biologics
Unlike biologics (e.g., TNF inhibitors, IL-6 blockers), which are administered by injection or infusion and target individual cytokines, JAK inhibitors are taken orally and act intracellularly on multiple signaling pathways simultaneously. This offers practical advantages in terms of administration, but requires careful consideration of the benefit-risk profile, particularly regarding safety.
References
- Smolen JS et al. - Rheumatoid arthritis. Nature Reviews Disease Primers, 2018. DOI: 10.1038/nrdp.2018.1
- European Medicines Agency (EMA) - JAK inhibitors: new measures to minimise risk of serious side effects. EMA/PRAC, 2023. Available at: https://www.ema.europa.eu
- Virtanen AT et al. - Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs, 2019. DOI: 10.1007/s40259-019-00362-9
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryCalcium ionophore therapy
Vascular wall thickening
Immune cell vitality markers
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: JAK inhibitors